BOZEMAN, Mont., May 18 /PRNewswire/ -- LigoCyte Pharmaceuticals
announced today that Donald Beeman has joined the company as their new
Chief Executive Officer. Most recently the President and Co-Founder of
Topaz Pharmaceuticals LLC, Mr. Beeman has over 25 years experience in top
executive positions in the pharmaceutical industry.
Before joining Topaz Pharmaceuticals, Mr. Beeman was the Vice President
of U.S. Commercial Operations for Merck's Vaccine Division. Mr. Beeman
established a strong leadership reputation at Merck, having held executive
positions in the Pharmaceutical and Marketing Divisions in both the United
States and Australia. "I am impressed with what LigoCyte has accomplished
and their strong vision for the future. I look forward to participating in
the company's growth," said Mr. Beeman.
"We are very pleased to have Don join our company at this exciting
time. As we prepare to take our Norovirus vaccine into the clinic, Don's
depth of expertise in all aspects of the pharmaceutical industry,
especially the vaccine market, will allow LigoCyte to aggressively move
forward as a clinical development company," said Dr. Robert Goodwin,
LigoCyte's President and COO.
Mr. Beeman joins Dr. Goodwin, Dr. Robert Bargatze, LigoCyte's Executive
Vice President & CSO, and Dr. Charles Richardson, LigoCyte's Executive Vice
President of Research & Development, in leading the company into its first
human clinical phase I trial.
About LigoCyte:
LigoCyte, established in 1998, is breaking new ground in the treatment
of inflammatory and infectious diseases. The company has produced a number
of novel drug compounds that modify immune responses by focusing on cell
binding interactions and their role in the immune system. LigoCyte is
advancing its proprietary products into human clinical testing, positioning
the company for continued growth and success in the biotechnology industry.
For additional information on LigoCyte, please visit http://www.ligocyte.com.
About LigoCyte's Norovirus Vaccine:
LigoCyte is developing a mucosal vaccine for the prevention of
Norovirus infection in humans, a temporarily debilitating illness that
afflicts nearly 23 million Americans annually. LigoCyte's program is
focused on an intranasally delivered, dry powder formulation. This approach
induces a robust immune response at the critical site of infection, the
gastrointestinal epithelium, and offers a shelf-stable formulation and
simple, pain-free administration. For additional information on LigoCyte's
Norovirus vaccine, please visit http://www.ligocyte.com/pdf/norovirus.pdf.
Binding Science. Better Medicine.
SOURCE LigoCyte Pharmaceuticals, Inc.
 back to top
Related links:
http://www.ligocyte.com/pdf/norovirus.pdf/
http://www.ligocyte.com/
CONTACT:
Karen Sipes, Ph.D., Director, Marketing and
Communications of LigoCyte Pharmaceuticals, Inc.,
+1-406-556-9228, karen.sipes@ligocyte.com
|
